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Allogenic Mesenchymal Stem Cells Versus
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in a Rabbit Model
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L. Selvaratnam,ll PhD, and T. Kamarul,y MS(Orth)
Investigation performed at Tissue Engineering Group, NOCERAL, Faculty of Medicine,
University of Malaya, Kuala Lumpur, Malaysia
Background: Mesenchymal stem cells (MSCs) represent a promising alternative form of cell-based therapy for cartilage injury.
However, the capacity of MSCs for chondrogenesis has not been fully explored. In particular, there is presently a lack of studies
comparing the effectiveness of MSCs to conventional autologous chondrocyte (autoC) treatment for regeneration of full-thickness
cartilage defects in vivo.
Hypothesis: Treatment with allogenic undifferentiated MSCs (alloMSCs) results in superior cartilage tissue regeneration profiles
when compared with autoC for repair of focal articular cartilage defects.
Study Design: Controlled laboratory study.
Methods: Full-thickness articular cartilage defects were created on the weightbearing surface of the medial femoral condyles in
both knees of New Zealand White rabbits (N = 30). Six weeks after the defect was induced, the right knee was treated with either
alloMSCs (n = 12) or autoC (n = 18), while the left knee remained untreated (control). The rabbits were sacrificed at 6 months after
treatment for assessment of cartilage tissue regeneration, which included the Brittberg morphologic score, histologic grading by
O’Driscoll score, and quantitative analysis of glycosaminoglycans per total protein content.
Results: Apart from significantly higher Brittberg scores in the alloMSC treatment group (8.8 6 0.8) versus the autoC treatment
group (6.6 6 0.8) (P = .04), both treatments showed similar cartilage regenerative profiles. All outcome measures were signifi-
cantly higher in the treatment groups compared with their respective controls (P\ .05).
Conclusion: AlloMSCs have similar effectiveness as autoC for repair of focal cartilage defects. Both treatments resulted in supe-
rior tissue regeneration compared with untreated defects.
Clinical Relevance: The results have an implication of supporting the potential use of MSCs for cartilage repair after sports
injuries or diseases, in view of similar efficacy but less patient morbidity and potential cost savings as compared with conventional
autoC therapy.
Keywords: mesenchymal stem cell; chondrogenic differentiation; cartilage repair; chondrocyte
Cellular therapy has been considered a successful treat-
ment modality for the repair of damaged articular carti-
lage, producing superior tissue repair quality as
compared with the standard surgical approach.11 The first
clinical trial reporting the efficacy of autologous chondro-
cyte implantation/transplantation (ACT/ACI), the conven-
tional form of cellular therapy, was published in 199412
after its success in animal studies in the preceding
years.20,50 Since then, ACI has been studied in many clin-
ical trials with good outcomes in the majority of
cases.4,12,34,36,41 Despite a successful historical perfor-
mance for more than 15 years, the use of ACI has not
been without limitations. Its recognized shortcomings
include donor-site morbidity, limited supply of chondro-
cytes, cellular dedifferentiation into fibroblast-like pheno-
type when cultivated in vitro, and inability to maintain
good tissue repair in the long term.10,28 It has been specu-
lated that the use of an alternative cell source such as mes-
enchymal stem cells (MSCs) might overcome these issues.
Mesenchymal stem cells may be harvested from many
potential donor sites including bone marrow, adipose
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tissue, trabecular bone, and other tissues without causing
damage to the unaffected cartilage.40 In addition, they
have a high proliferative capacity, and owing to their mul-
tipotency, these cells can conveniently be manipulated in
vitro to differentiate into chondrocytes for subsequent
use in cartilage regeneration.14,18,31,43
There have been many previous reports involving in vivo
experiments describing good repair outcomes after trans-
plantation of MSCs in cartilage defects. Wakitani et al49
in 1994 were among the first research groups to report
the successful transplantation of bone marrow–derived
MSCs in osteochondral defects in rabbit models. Other
researchers have also studied the application of allogenic
or autologous bone marrow–derived MSCs using different
scaffolds with or without the addition of growth factors to
treat cartilage defects in various animal models.19,22,37
While the use of autologous chondrocytes (autoC) and allo-
genic undifferentiated MSCs (alloMSCs) to repair damaged
cartilage have been forthcoming in many studies, it has
been demonstrated that additional use of scaffolds enhances
the tissue repair.2,13,22,48,55 These scaffolds not only provide
a convenient method for delivering cells into focal defect
sites, but also provide structural support to the construct
and induce cartilage matrix formation within the defective
sites.47,48,55 Alginate is a well-established biomaterial for
use in these conditions.8,23,30,33,48,52 Not only is this material
biocompatible, the embedded chondrocytes maintain their
phenotype and produce more depositions of extracellular
cartilaginous matrix in alginate.16
Despite a multitude of available experimental reports on
a cell-based approach for articular cartilage repair, there is
presently limited exploratory research comparing alloMSCs
with other sources of chondrocytes, particularly those
obtained from the autologous transplantation procedure
(autoC). To date, there is only 1 prospective clinical study
comparing the effectiveness of MSCs against autoC for
repairing damaged cartilage in humans.38 The study
revealed similar clinical outcomes between MSCs and autoC
assessed postoperatively by a multifaceted questionnaire-
based clinical evaluation carried out throughout a temporal
course of 2 years. While it may be appropriate to use the val-
idated knee cartilage outcome clinical instruments to assess
the overall function of the repaired cartilage tissue, it is
equally important to ascertain the changes in tissue repair
quality in response to both treatments. However, these forms
of investigation are usually confined to animal models since
the invasiveness of the tissue biopsy procedure may not nec-
essarily be tolerated by human subjects in the clinical set-
ting. A study incorporating more objective assessments of
tissue repair is therefore required to determine the cellular
changes that may exist during the transplantation process.
This may demonstrate a clear distinction in the physical fea-
tures of the repaired cartilage tissue resulting from the indi-
vidual treatment. No parallel comparative analysis of
tissue-healing outcome has been previously performed to
evaluate the effectiveness of alloMSCs compared with autoC
in animal studies. Therefore, the aim of the current study is
to compare in a more objective manner the effectiveness of
the 2 different forms of cell-based therapy (alloMSCs vs
autoC) in repairing focal cartilage defects in an in vivo rabbit
model, by analyzing the gross morphology, histology, and
extracellular matrix protein content such as glycosamino-
glycan in response to transplantation of chondrocytes from
these distinct sources into the defective areas in the joint.
MATERIALS AND METHODS
Rabbit Focal Articular Cartilage Defect Model
Thirty male New ZealandWhite (NZW) rabbits aged between
5 and 6 months and weighing approximately 2.5 kg were ran-
domly assigned into 2 treatment groups: ACI group (autoC; n
= 18) and allogenic MSC group (alloMSC; n = 12). The sample
size of each treatment group was calculated based on 2 inde-
pendent studies previously conducted in our laboratory com-
paring MSCs and autoC treatments with their respective
control groups,15,29,30 in view of the lack of reference data
involving direct parallel comparison between the 2 treatment
groups using similar objective measurements. The stated
number of subjects in each group was required to detect 2-
fold difference in Brittberg scores between the treated and
untreated groups with 80% power at a .05% significance
level. In addition, 3 rabbits were sacrificed separately to har-
vest bone-marrow–derived MSCs for use in the alloMSC-
treated group. This study was approved by University of
Malaya animal ethics committee and the experiments were
carried out in accordance to the regulations imposed by the
university and the appropriate Malaysian government regu-
latory body (OS/05/07/2006/TKZ/A[R] and PM/24/06/2008/
TKZ[c][R]).
The rabbits were anesthetized before both femorotibial
joints were surgically exposed. A 5-mm–diameter full-
thickness articular cartilage defect was created in both knees
using a custom-made chondrotome as previously described
by Kamarul et al in 2008.30 All defects were created on the
weightbearing portion of the medial femoral condyle. Carti-
lage from the operated sites were removed from both knees
and collected aseptically in 13 phosphate-buffered saline
solution (PBS; pH 7.4) (Gibco/Invitrogen, Carlsbad,
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California) supplemented with 4% penicillin-streptomycin
(Invitrogen). The cartilage specimens were kept at 4C before
further processing of chondrocytes. The wounds were surgi-
cally closed in layers with 5-0 Vicryl absorbable sutures
(Ethicon, Johnson & Johnson, Somerville, New Jersey) and
bandages. All surgeries were done in accordance with the
standard procedures under sterile surgical conditions. Post-
operatively, the animals were transferred into the cages
without immobilization. All animals were closely monitored
for infections and other complications.
Isolation of AutoC and Allogenic MSCs
Autologous chondrocytes were isolated under sterile condi-
tions from cartilage tissues in accordance with the techni-
ques previously described by Ab-Rahim et al in 2008.1 The
specimens were first digested using 0.6% type II collage-
nase (Sigma-Aldrich, St Louis, Missouri) at 37C and
rotated overnight followed by centrifugation at 500g for
10 minutes. The supernatant was discarded and the cell
pellet was resuspended in 1 mL of Dulbecco’s Modified
Eagle Medium (DMEM; Invitrogen). The resuspended cells
were then seeded into a T75 flask (Corning, Lowell, Massa-
chusetts) containing DMEM/Ham’s F-12 Nutrient Mixture
(1:1) (Invitrogen) supplemented with 10% fetal bovine
serum (FBS; HyClone, Logan, Utah), 0.0025% ascorbic
acid (Sigma), and 1% penicillin-streptomycin. The autoCs
were maintained in monolayer culture at 37C, 95%
humidity, and 5% CO2 for 3 weeks while the growth
medium was exchanged every 2 to 3 days.
To obtain alloMSCs for transplantation, 3 rabbits were
sacrificed using an intravenous overdose of pentobarbital.
Femurs and tibias of both lower limbs were removed and
any adherent tissues were discarded. All harvested bones
were kept on ice in 13 PBS solution supplemented with
4% penicillin-streptomycin until they were processed. Within
3 hours, bone marrow was harvested from femurs and tibias.
AlloMSCs were isolated according to an established protocol
described by Pittenger et al in 1999.42 Briefly, 2 mL of bone
marrow was diluted with 13 PBS solution (1:2) and loaded
over 3 mL Ficoll-paque (GE Healthcare–Amersham Bioscien-
ces, Piscataway, New Jersey) in a 15-mL Falcon tube (Corn-
ing). Mononuclear cells were harvested from the interface of
plasma and Ficoll-paque after centrifugation at 2200 rpm for
25 minutes. The cells were then washed with prewarmed
DMEM and centrifuged for another 10 minutes. The cell pel-
let was resuspended in DMEM containing 10% FBS and 1%
penicillin-streptomycin and seeded into a T75 flask. All cells
were maintained and incubated under the same conditions as
described above. After 8 days, the nonadherent cells were
removed while the adherent cells (alloMSCs) were replen-
ished with fresh medium. The alloMSC culture was also
maintained in monolayer for 3 weeks in a similar environ-
ment to that of the autoC culture.
Autologous Chondrocytes (AutoC)
and AlloMSC Culture in Alginate
Autologous chondrocytes and alloMSC alginate beads
were prepared in 1.2% low-viscosity alginate solutions
(Sigma-Aldrich) in 0.15 M sodium chloride as previously
described by Kamarul et al30 after 21 days of monolayer cul-
ture. Autologous chondrocytes and alloMSCs were first
detached from the T75 flask surface using TypLE express
(Invitrogen) and pelletized in a separate 15-mL Falcon
tube. Cell count was performed, followed by the addition of
the appropriate volume of alginate solution to form alginate
beads, each containing approximately 5.0 3 105 cells. The
cell suspension was mixed thoroughly and expressed slowly
through a micropipette tip into a 102-mM calcium chloride
solution. After 10 minutes of polymerization in the solution,
the alginate beads were washed with 0.15 M sodium chloride
to remove the excess calcium chloride. Five autoC-alginate
beads were transferred to each of the 24-well culture plates
(Becton Dickinson, Durham, North Carolina) and cultured
in DMEM/F12 containing 10% FBS, 25 mg/mL ascorbic
acid, 50 mg/mL gentamicin (Invitrogen), and 360 mg/mL
L-glutamine (Invitrogen). The alloMSC-alginate beads were
cultured in DMEM low glucose containing 10% FBS and
1% penicillin-streptomycin. Both cultures in the alginate
scaffold were maintained at 37C in a humidified environ-
ment of 5% CO2 for another 3 weeks.
Implantation of AutoC-Alginate and AlloMSC-Alginate
Constructs Into Defective Areas
To avoid dedifferentiation of autoC, implantation of autoC
and alloMSC embedded in alginate beads into the rabbits’
cartilage defects was carried out after 3 weeks of cell culture
in the alginate constructs, culminating in an overall culture
period of 6 weeks (ie, 3 weeks in monolayer and 3 weeks in
alginate construct) after the creation of the defect. All trans-
plantations were performed only in the right knee of each rab-
bit. The rabbits were anesthetized and the chondral defects
were exposed and identified. A periosteum flap of 7-mm diam-
eter was harvested from the medial aspect of the proximal
tibia of the same limb. The periosteum flap was then placed
on top of the defect and anchored with 1 suture in each corner
using 8-0 Vicryl absorbable sutures. Two beads of either
autoC-alginate or alloMSC-alginate (total of 1 3 106 cells)
were inserted underneath the flap according to the respective
treatment group. The remaining opening of the periosteum
flap was then sealed using Tisseel fibrin glue (Baxter AG
Industries, Vienna, Austria) and suture (11-0 Vicryl absorb-
able suture). The wound was closed in layers using absorb-
able suture and bandages, followed by application of
antiseptic solution to prevent infection. The left knees were
left untreated (control group). All transplanted rabbits were
treated with analgesic and antipyretic, Metacam (Boehringer
Ingelheim, Berks, United Kingdom) and Kombitrim (KELA
Laboratoria NV, Hoogstraten, Belgium) for 3 days after the
operation, both of which additionally act as broad-spectrum
antibiotics for both gram-positive and gram-negative bacteria.
Harvesting and Gross Examination of the
Regenerated Tissues From Defective Areas
At 6 months after implantation, the rabbits’ knee joints
were surgically removed and examined. For gross
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evaluation, all specimens were examined under direct light
microscopy by 2 independent observers, both experienced
orthopaedic surgeons, who were blinded to the sample
groups. The observers were asked to examine and grade
samples according to the Brittberg scoring system.13 Upon
completion of the scoring, the specimens were halved using
a mechanical bone saw (Fein MultiMaster Accu, C & E Fein
Gmbh, Stuttgart, Germany). This was done carefully to
avoid any alteration or destruction of the tissue specimen
according to the technique previously established by
Kamarul et al.29,30 Half of each specimen was fixed in
10% phosphate-buffered formalin (4% formaldehyde) for
histology and immunostaining, while the other half was uti-
lized for analysis of the glycosaminoglycan (GAG) content.
Histologic Examination and
Immunohistochemical Staining
Specimens that were fixed in 4% buffered formalin were
decalcified. Fixed and decalcified tissues were subsequently
dehydrated in ethanol in a stepwise manner from 70% up to
100%, transferred to xylene, and embedded in paraffin. At
the center of each sample, 5-mm paraffin sections were pre-
pared and placed on glass slides, dried overnight, and stored
at 4C. The samples were stained with hematoxylin and
eosin for general morphologic evaluation and safranin
O–fast green to detect proteoglycan. Immunohistochemical
staining was performed using DAKO EnVision 1 System
peroxidase kit (DAKO, Glostrup, Denmark). The specimen
section slides were incubated in primary antibody solution
(anti–collagen type II, Santa Cruz Biotechnology, Santa
Cruz, California) followed by secondary antibody and
substrate-chromogen solution in accordance with the manu-
facturer’s instructions. The O’Driscoll cartilage scoring was
used for histologic and histochemical assessment of the
repaired cartilage specimens. The scoring was performed
by 2 histologists blinded to the group status.
Biochemical Assay for GAG
The Blyscan GAG assay kit (Biocolor Ltd, Antrim, United
Kingdom) was used to evaluate GAG content of the regen-
erated cartilage tissues in both treatment groups. Speci-
mens were dissected into small pieces using a scalpel and
digested using RIPA buffer (Merck & Co, Whitehouse Sta-
tion, New Jersey) supplemented with protease inhibitors
(Sigma) for 1 hour. Aliquots of each sample were mixed
with DMMB (dimethylmethylene blue) dye and reagents
(Biocolor) according to the manufacturer’s instructions.
The absorbance at 656 nm was measured using the spec-
trophotometer and compared with a standard plot of chon-
droitin sulphate provided by the manufacturer for
quantitative determination of the GAG content.
Statistical Analysis
Statistical analysis was performed using SPSS statistical
software (version 17.0, SPSS Inc, an IBM company, Chi-
cago, Illinois). The values of Brittberg and O’Driscoll scores,
as well as GAG concentrations for all tissue samples, were
presented as mean 6 standard deviation. Comparisons of
variables between the 2 treatment groups were analyzed
using the parametric 2-sided independent t test. Differences
were considered statistically significant at P\ .05.
RESULTS
Gross Appearance of Defect
Figure 1 illustrates an example of the gross macroscopic
analysis of the representative tissues from the alloMSC,
autoC, and control groups. Macroscopic examinations at
6 months after implantation revealed that defects treated
with both alloMSCs and autoC showed good filling, with
the surface appearing flush and smooth (Figures 1D and
1E). In contrast, none of the untreated defects in the left
knees (control) (Figure 1F) showed complete filling as com-
pared with the treated knees.
Figure 2 shows the results of Brittberg scores reflecting
quantitative macroscopic evaluation of the tissue regenerate
quality between the alloMSC and autoC treatment groups
together with their respective controls. Both the alloMSC
and autoC implantations showed superior cartilage regener-
ation quality as compared with the untreated left knees, as
evidenced by the significantly higher Brittberg scores in the
treatment groups (8.8 6 0.8 vs 3.0 6 0.8 for the alloMSC-
control pair, and 6.6 6 0.8 vs 2.3 6 0.6 for the autoC-control
pair; both pairs were associated with a P value of .001). The
difference in Brittberg scores between alloMSC and autoC
was significant (P = .04) from the 2-sided independent
t test. No significant differences in the Brittberg scores
were found between the untreated left knees (control) in
both alloMSC and autoC groups (P = .31).
Histologic and Immunohistochemical Appearance
of the Regenerated Cartilage Tissues
Figure 3 shows the results of the microscopic examination
of the regenerate tissues in 4 groups (ie, the alloMSC-trea-
ted group, the autoC-treated group, the untreated group
[negative control] and a representative specimen of a nor-
mal NZW rabbit’s knee articular cartilage tissue [positive
control]). The microscopic appearance of the tissue using
various staining methods revealed cartilage regeneration
within the treated sites although some areas appeared to
be infiltrated by a small amount of fibrous tissues. In con-
trast, the untreated defects did not appear to undergo com-
plete healing, but were merely filled with soft tissue
instead (Figures 3C, 3G, and 3K). In the hematoxylin
and eosin–stained sections, cartilage from the alloMSC-
treated group (Figure 3A) showed substantial thickening
of the cartilage tissue compared with the untreated defect
(Figure 3C), with the chondrocytes arranged in clusters.
Similar cartilage tissue thickening was also observed in
the autoC-treated group (Figure 3B); however, the chon-
drocytes were mostly found in columnar formations. The
regenerated tissues from both treatment groups showed
a continuous surface with a mixture of hyaline and fibro-
cartilage. Immunohistochemical staining for type II
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collagen further confirmed that both the alloMSC- and
autoC-treated tissue sections showed a relatively higher
expression of cartilaginous collagen (Figures 3E and 3F)
compared with that of the untreated defects (Figure 3G).
The alloMSC- and autoC-treated tissue sections also
showed relatively heavier staining with safranin O
(Figures 3I and 3J) compared with the untreated defect
(Figure 3K), suggesting a higher concentration of proteo-
glycans, one of the major components of cartilage tissue.
The average difference in the O’Driscoll score (ie, quan-
titative histologic grading of the tissues) between the treat-
ment groups appeared to be very small and nonsignificant
(Figure 4), with mean values of 11.2 6 0.8 and 13.5 6 2.4
for alloMSC and autoC groups, respectively (P. .05). How-
ever, both treatment groups had significantly higher
O’Driscoll scores compared with their respective controls.
The mean O’Driscoll score for the alloMSC-control was
8.2 6 0.7, and that for the autoC-control was 6.7 6 2.1.
Figure 2. Brittberg scores of articular cartilage regeneration
in alloMSC and autoC treatment groups were compared with
their respective control on the contralateral side 6 months
after transplantation. The Brittberg score was significantly
higher in alloMSC compared with autoC. Both treatments
were associated with significantly higher scores compared
with their respective control groups. alloMSC, allogenic
undifferentiated mesenchymal stem cells; autoC, autologous
chondrocytes. *Significant difference from untreated, nega-
tive control (P \ .01). #Significant difference between
alloMSC and autoC group (P\ .05).
Figure 3. Immunohistochemical staining of rabbit femoral
condyles from alloMSC-treated (A, E, I), autoC-treated (B,
F, J), and untreated (C, G, K) tissues at 6 months after trans-
plantation. A representative specimen of a normal cartilage
tissue is shown (D, H, L) as a reference for evaluation of
the normal cartilage healing. The type II collagen is stained
in brown, and the safranin O (ie, a measure of proteoglycans
characterizing cartilage tissue) is stained in red. alloMSC,
allogenic undifferentiated mesenchymal stem cells; autoC,
autologous chondrocytes. Scale bars = 100 mm.
Figure 4. Quantitative histologic evaluation of the regener-
ated cartilage using O’Driscoll scores at 6 months after treat-
ment with alloMSC and autoC together with their respective
controls. Results showed significantly higher scores in the
treatment groups compared with their controls. However,
there are no significant differences in the scores between
the 2 treatment groups. alloMSC, allogenic undifferentiated
mesenchymal stem cells; autoC, autologous chondrocytes.
*Significant difference from untreated, negative control
(P\ .01).
Figure 1. Macroscopic evaluation of the defective areas on
articular cartilage from the alloMSC, autoC, and control
groups before treatment (A, B, and C, respectively) and 6
months after transplantation (D, alloMSC; E, autoC; and F,
control). There was incomplete filling of the control knee, while
the defect appeared completely filled by both alloMSC and
autoC transplantation. alloMSC, allogenic undifferentiated
mesenchymal stem cells; autoC, autologous chondrocytes.
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Glycosaminoglycan Concentrations
in the Regenerated Tissues
Quantitative determination of GAG levels in the tissue sam-
ples revealed a dramatic and significant increase in GAG
concentrations in both the alloMSC- and autoC-treated knees
as compared with the untreated knees (P = .001). However,
there was no significant difference in GAG levels between
the 2 treatment groups (P = .74). The mean GAG/protein con-
centrations in the treated knees were 1.7 6 0.3 and 1.8 6
0.5 mg GAGs/mg proteins for the alloMSC and autoC groups,
respectively. For the control knees, the mean GAG/protein
concentrations for the alloMSC and autoC groups were
1.0 6 0.2 and 1.1 6 0.3 mg GAGs/mg proteins, respectively
(Figure 5). No significant differences for both knees were
observed between these groups (P . .05).
DISCUSSION
The use of both autoC and alloMSCs produced comparable
cartilage repair outcome, and was significantly better than
those left untreated. Although the superior outcome of
using cell-based therapy is not unexpected, it is anticipated
that differences between the use of both cell sources should
have been evident in the study. In particular, alloMSC is
postulated to result in superior tissue repair as compared
with autoC in view of the numerous advantages potentially
conferred by MSCs in cartilage regeneration, as further
discussed in this section. In the current study, the morpho-
logic, histologic, and biochemical profiles of the regener-
ated cartilage tissue using the two cell sources were
compared. This was envisaged to provide more objective
evidence and further insight into the effectiveness of the
repair process following either alloMSC or autoC
treatment. To the best of our knowledge, this study is the
first to report the results of direct parallel comparison
between autoC and alloMSC for repair of focal cartilage
defects in an animal model in vivo.
The complementing results observed from the various
parameters examined in this study support the findings
that cell therapies induce cartilage regeneration after
injury.13,15,20,22,30,50 Histologic observations revealed sev-
eral notable features that may be of interest. In the
alloMSC-treated group, chondrocytes in the histologic sec-
tions appeared to be clustered in groups, while in the
autoC-treated group, cells were in columnar arrangements.
However, the difference in the histologic appearance
between the 2 treatment groups did not appear to affect
the O’Driscoll histologic score. It is unclear whether the dif-
ferent structural arrangements and orientation of cells
within the repair site result in any significant alterations
in the cartilage biomechanical function. Further studies
investigating potential correlation between the different
histologic structures of the regenerated cartilage and its bio-
mechanical integrity would be of substantial value.
The outcomes of the present study appear to support the
clinical findings published by Nejadnik et al,38 who concluded
that transplanted autologous bone marrow–derived MSCs in
patients is as effective as ACT. An apparent limitation noted
in the referred study is that there was an absence of stan-
dardization of variables such as the size and the depth of car-
tilage defects as well as patient age. These factors might
affect the healing process and therefore could potentially con-
found the results of the study. It was previously demon-
strated that increased passages and donor age contributed
toward reducing the rate of MSC differentiation, which is crit-
ical to cartilage healing.7,9,45,46 Thus, we attempted to over-
come this issue by conducting an animal study in a more
controlled environment, which included ensuring the unifor-
mity of defect size, homogeneous cartilage tissue, similar ani-
mal age, and using an animal from a smaller genetic pool.
Apart from using animals within a narrow margin of age
group, parallel comparison between the treated and
untreated groups was conducted within the same animal in
the present study. The use of cells embedded in alginates
for transplantation was necessary to ensure that transplanta-
tion could be conducted more conveniently in a standardized
manner. In addition, MSCs maintained in a 3-dimensional
environment such as that provided by the alginate scaffold
promotes chondrogenic differentiation and produces selective
upregulation of cartilage-specific genes.17,26,52 Previous stud-
ies have also shown that chondrocytes in alginate beads
remain viable up to 8 months in culture and produce cell-
associated matrix similar to hyaline articular cartilage.21,23-25
The use of MSCs as a treatment approach for articular
cartilage injury should be considered since it is associated
with a greater number of advantages and has comparable
efficacy to that of ACI. One of the established limitations of
ACI is the insufficiency in cell supply. Autologous chondro-
cyte implantation is commonly associated with limited
ability of the harvested chondrocytes to proliferate and
undergo differentiation.35 In contrast, MSCs have a higher
capacity of self-replication and differentiation both in vitro
and in vivo.44 Mesenchymal stem cells are also versatile
Figure 5. Comparison of the glycosaminoglycan (GAG) con-
centrations in the alloMSC and autoC treatment groups with
their respective control groups, showing significant differen-
ces between each treatment with its respective control but
no significant differences between the 2 treatment groups.
alloMSC, allogenic undifferentiated mesenchymal stem cells;
autoC, autologous chondrocytes. *Significant difference
from untreated, negative control (P\ .05).
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and can be expanded for a prolonged period of time without
transforming into other cell phenotypes.32,54 On the con-
trary, chondrocytes often lose their cartilaginous pheno-
type during expansion in monolayer culture.5,6
Mesenchymal stem cells can facilitate homing and engraft-
ment of other stem cells, which may facilitate tissue heal-
ing. They can potentially be mobilized into the circulation
in response to injury signals, and exert their reparative
effects at the site of injury.31 However, despite all of these
advantages, it should be appreciated that the entire pro-
cess of MSC harvest and implantation is rather complex
and should be well understood before its application in
the clinical field. The use of allogenic MSCs (or alloMSCs)
in clinical applications has yet to be ascertained, although
several studies using animal models have shown promising
results.3,15,37,49,51,53 While there may be concerns of graft
rejection and poor tissue healing because of immune-
incompatibility between alloMSCs and the host tissues,
in vitro studies suggest that human leukocyte antigen
(HLA)–mismatched MSCs do not provoke an immune
response in the host and are even able to suppress allo-
genic lymphocyte proliferation.39 However, alloMSC trans-
plantation in humans needs to be further investigated in
a rigorous manner to ensure that this potential therapeutic
strategy remains free from any considerable problems.
Our study presents several limitations that are worth
noting. Because of constrained financial resources, the tis-
sue analyses could not be further extended into biochemi-
cal evaluation and/or gene expression analysis. Financial
restriction also prohibited functional assessment of the
repaired site (eg, biomechanical testing). Thus, it was diffi-
cult to ascertain whether the observed difference in histo-
logic appearance of the regenerated cartilage between
alloMSCs and autoC affects the biomechanical function of
the tissues. Nevertheless, we consider that this study still
provides valuable findings since the conclusions were
drawn using well-accepted experimental techniques uti-
lized in several other previous studies.27,38,53 Introduction
of another treatment arm that utilizes a standard treat-
ment approach for cartilage repair, such as subchondral
drilling or microfracture, would have led to a more compre-
hensive conclusion. However, since the study was not
designed to validate alloMSC or autoC against a standard
treatment procedure, as well as the limitation in resources,
this action was not pursued. Improvement could also be
made to the study by using autologous MSCs instead of
allogenic sources. This, however, can only be performed
in larger animal models, given that extracting MSCs
from rabbit marrow may prove to be too challenging. The
issue of cell viability following cell culture in alginate
between the 2 treatment groups was not specifically
addressed in the current study, which could be further
incorporated in future studies.
In conclusion, chondral defects treated with allogenic
MSCs or autoC produced hyaline-like repair tissue that
had significantly better quality than that of the control
untreated knees. However, both alloMSC and autoC demon-
strated comparable tissue regenerative profiles. In view of
the additional advantages conferred by MSCs, such as
self-renewal ability ensuring sufficient cell supply and
lesser donor-site morbidity, the use of MSCs to treat full
thickness articular cartilage defects remains a viable and
attractive therapeutic option. Nevertheless, caution should
be exercised when translating these findings into clinical
applications owing to the intrinsically rapid healing poten-
tial of rabbits compared with human cartilage. A better
understanding of the complex molecular events that are
involved in chondrogenesis induced by MSCs and the
in vivo integration of cell constructs with the native articu-
lar cartilage is required before widespread use of MSCs
could be strongly advocated in the clinical field.
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